Trial · NCT00911053
Melatonin for Circadian Sleep Disorders in the Blind
NCT00911053, Not applicable, Terminated, Oregon Health and Science University; results first posted 2019-11-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Melatonin for Circadian Sleep Disorders in the Blind. Trials, record NCT00911053. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00911053
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Melatonin for Circadian Sleep Disorders in the Blind
- NCT number
- NCT00911053
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 59 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- Insomnia, Blindness, Daytime Sleepiness
- Interventions
- Melatonin, Regular Sleep Schedule, Light
- First posted
- 2009-06-01
- Last updated
- 2019-11-27
- Results first posted
- 2019-11-27
- Limitations and caveats
Analyses were not completed because a unique provision in the American Recovery and Reinvestment Act (ARRA) of 2009 funding source unexpectedly prevented approval of a second year no-cost-extension in which completion of analyses were planned.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Effects on Circadian Phase Will be Assessed During Each Trial by Measuring the Timing of Endogenous Melatonin Secretion. | 1 year | |
| Secondary | Treatment Effects on Sleep and Alertness Will be Assessed by Daily Diaries and Daily Wrist Actigraphic Monitoring. Subjective Benefits Will be Assessed With Daily Ratings of Alertness and Vigor. | 1 year |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Treatment Effects on Circadian Phase Will be Assessed During Each Trial by Measuring the Timing of Endogenous Melatonin Secretion. | 1 year | The PI has retired from the institution. Sincere efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available. | ||
| SECONDARY | Treatment Effects on Sleep and Alertness Will be Assessed by Daily Diaries and Daily Wrist Actigraphic Monitoring. Subjective Benefits Will be Assessed With Daily Ratings of Alertness and Vigor. | 1 year | The PI has retired from the institution. Sincere efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Baseline | 0 | |
| Overall Study | STARTED | Melatonin | 0 | |
| Overall Study | STARTED | Light | 0 | |
| Overall Study | STARTED | Regular Sleep Schedule | 0 | |
| Overall Study | STARTED | Longitudinal Monitoring | 0 | |
| Overall Study | COMPLETED | Baseline | 0 | |
| Overall Study | COMPLETED | Melatonin | 0 | |
| Overall Study | COMPLETED | Light | 0 | |
| Overall Study | COMPLETED | Regular Sleep Schedule | 0 | |
| Overall Study | COMPLETED | Longitudinal Monitoring | 0 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Baseline | 0 | 0 |
| Total, all-cause mortality | Melatonin | 0 | 0 |
| Total, all-cause mortality | Light | 0 | 0 |
| Total, all-cause mortality | Regular Sleep Schedule | 0 | 0 |
| Total, all-cause mortality | Longitudinal Monitoring | 0 | 0 |
| Total, other adverse events | Baseline | 0 | 0 |
| Total, other adverse events | Melatonin | 0 | 0 |
| Total, other adverse events | Light | 0 | 0 |
| Total, other adverse events | Regular Sleep Schedule | 0 | 0 |
| Total, other adverse events | Longitudinal Monitoring | 0 | 0 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01EY018312 | Melatonin for Circadian Sleep Disorders in the Blind | LEWY, ALFRED J | OREGON HEALTH & SCIENCE UNIVERSITY | NATIONAL EYE INSTITUTE | 2007 to 2011 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00911053
GET https://conductscience.org/api/trials/v1/NCT00911053/registered